CEO: Yuichi Iwaki.
Revenue: No revenues for 2011 and 2010.
Net loss: Net loss of $17.7 million 2011; net loss of $20.2 million in 2010.
No. of local employees: 13.
Headquarters: UTC area of San Diego.
Year founded: 2000.
Stock symbol and exchange: MNOV on Nasdaq Global Market. Code number 4875 on Jasdaq Market of the Osaka Securities Exchange.
Company description: A publicly-traded biopharmaceutical company focused on acquiring and developing novel therapeutics from Japanese biopharma companies for unmet medical needs in the United States and elsewhere.
Key factors for success: Utilizing the company’s strong ties within the Japanese pharmaceutical industry, MediciNova acquires therapeutic candidates with proven safety data from mid-size Japanese companies. MediciNova is developing these therapeutic candidates for medical needs in the U.S. and other global markets.
It’s rare for the Japanese to develop drug compounds outside their country due to differences in regulatory standards, guidelines and culture...